Skip to main content

Branded

  • FDA extends NDA review for Novartis' COPD treatment

    BASEL, Switzerland — The Food and Drug Administration has extended its regulatory review period for Novartis' new drug application for its once-daily, long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, as well as chronic bronchitis and/or emphysema, the drug maker said.

  • Study: GERD sufferers don't discuss symptoms with doctors

    BETHESDA, Md. — Most patients that suffer from gastroesophageal reflux disease or persistent heartburn symptoms rarely speak with a healthcare provider about their condition, according to a new study conducted on behalf of the American Gastroenterological Association, in partnership with drug maker Takeda.

  • AACE, Takeda say online resource will provide accurate healthcare information

    JACKSONVILLE, Fla., and DEERFIELD, Ill. — The American Association of Clinical Endocrinologists has teamed up with drug maker Takeda to develop an online resource that will be reviewed and evaluated by top medical experts.

    AACE and Takeda will offer a compendium of existing reliable resources specific to Type 2 diabetes, divided into various categories (e.g., management, lifestyle and tools) and reviewed by experts to help healthcare professionals guide their patients and caregivers as they attempt to cut through the clutter of the many resources available.

  • Cephalon's oncology portfolio to get boost with Gemin X acquisition

    FRAZER, Pa. — Cephalon plans to acquire a privately owned company developing treatments for cancer, Cephalon said Monday.

    The Frazer, Pa.-based drug maker said it would pay $225 million upfront for Malvern, Pa.-based Gemin X, and Gemin X stockholders would be eligible to receive up to $300 million in milestone payments related to products under development.

    Gemin X specializes in cancer treatments that target and kill cancer cells. Its lead product is GX15-070 (obatoclax), currently in phase-2b clinical development as a treatment for small cell lung cancer.

  • Valeant CEO named chairman of the board

    MISSISSAUGA, Ontario — J. Michael Pearson has been appointed to chairman of the board at Valeant Pharmaceuticals, the drug maker said Tuesday.

    Pearson, who is Valeant's CEO, will extend his contract with Valeant through February 2017, the company said.

    Pearson replaces current chairman Robert Ingram, who remains on the board as an independent board director and lead director.

  • Many nasal allergy sufferers don't have control over symptoms

    SAN FRANCISCO — Less than 20% of surveyed patients with nasal allergies find their symptoms are completely controlled over a one-week period of treatment, according to a survey performed by drug maker Teva Pharmaceutical Industries.

  • Report: Mylan looks to block Ranbaxy from making generic Lipitor

    NEW YORK — Generic drug maker Mylan is suing the Food and Drug Administration in an effort to prevent Gurgaon, India-based competitor Ranbaxy Labs from launching its generic version of Pfizer’s cholesterol medication Lipitor, according to published reports.

  • Lilly issues warning over alcohol prep pads associated with Forteo

    INDIANAPOLIS — Drug maker Eli Lilly is warning patients to avoid using alcohol prep pads that come with one of its osteoporosis drugs due to the risk of bacterial infections.

X
This ad will auto-close in 10 seconds